

Technology Guidance

Durvalumab

for treating resectable muscle invasive bladder cancer

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended durvalumab for inclusion on the MOH List of Subsidised Drugs, when used in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by adjuvant durvalumab monotherapy after radical cystectomy for muscle invasive bladder cancer. The Committee considered that the company's proposal, including the price-volume agreement, was not acceptable.

Clinical indication, subsidy class and MediShield Life claims eligibility for durvalumab are provided in the Annex.

ANNEX

Recommendations by the MOH Drug Advisory Committee

Drug preparation	Company-proposed clinical indication	Subsidy class	Eligible for MediShield Life claims
Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion	Durvalumab in combination with gemcitabine and cisplatin as neoadjuvant treatment followed by adjuvant durvalumab monotherapy after radical cystectomy for the treatment of muscle invasive bladder cancer.	Not recommended for subsidy	No

 Agency for Care Effectiveness - ACE
  Agency for Care Effectiveness (ACE)

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidelines, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about-us/

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore
 Email: ACE@moh.gov.sg

In citation, please credit "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.